Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew G Cyr

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cold Spring Harbor Protocols|October 15, 2024
Cloning, Expression, and Purification of Phage Display-Selected Fab for Biophysical and Biological StudiesMatthew G Cyr, Haiyong Peng, Christoph Rader
Journal of Molecular Biology|April 5, 2023
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multi-omic Target DeconvolutionMatthew G Cyr, Henry D Wilson, Anna-Lena Spierling, et al.
Nature Communications|June 18, 2024
Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemiaJessica Nunes, Rakeb Tafesse, Charlene Mao, et al.
Leukemia|February 26, 2021
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemiaDamian Kovalovsky, Jeong Heon Yoon, Matthew G Cyr, et al.
Cancer Immunology Research|July 8, 2018
Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation AntibodiesJing Chang, Haiyong Peng, Brian C Shaffer, et al.
Journal for Immunotherapy of Cancer|November 28, 2022
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemiaMatthew G Cyr, Maissa Mhibik, Junpeng Qi, et al.
Scientific Reports|June 23, 2018
A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano LuciferaseNatalia J Martinez, Rosita R Asawa, Matthew G Cyr, et al.
Nature Communications|January 17, 2026
A small molecule VDAC ligand inhibits ERAD and induces selective cancer cell death via disruption of calcium homeostasisWenjing Yan, Daniel C Talley, Antara Syam, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cold Spring Harbor Protocols|October 15, 2024
Cloning, Expression, and Purification of Phage Display-Selected Fab for Biophysical and Biological StudiesMatthew G Cyr, Haiyong Peng, Christoph Rader
Journal of Molecular Biology|April 5, 2023
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multi-omic Target DeconvolutionMatthew G Cyr, Henry D Wilson, Anna-Lena Spierling, et al.
Nature Communications|June 18, 2024
Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemiaJessica Nunes, Rakeb Tafesse, Charlene Mao, et al.
Leukemia|February 26, 2021
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemiaDamian Kovalovsky, Jeong Heon Yoon, Matthew G Cyr, et al.
Cancer Immunology Research|July 8, 2018
Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation AntibodiesJing Chang, Haiyong Peng, Brian C Shaffer, et al.
Journal for Immunotherapy of Cancer|November 28, 2022
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemiaMatthew G Cyr, Maissa Mhibik, Junpeng Qi, et al.
Scientific Reports|June 23, 2018
A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano LuciferaseNatalia J Martinez, Rosita R Asawa, Matthew G Cyr, et al.
Nature Communications|January 17, 2026
A small molecule VDAC ligand inhibits ERAD and induces selective cancer cell death via disruption of calcium homeostasisWenjing Yan, Daniel C Talley, Antara Syam, et al.
Pageof 1